Redcare Pharmacy Faces Dual Challenges as Key Payment and New Rival Loom
Published on 01/01/2026 at 21:01 | Redaktion boerse-global.de
Redcare Pharmacy is entering 2026 under significant strain. The MDAX-listed company’s shares have lost approximately half their value over the past twelve months, trading perilously close to the €65 mark. Management is confronting pressure from two sides: a substantial payment due in January and an aggressive new competitor targeting its core business.
Perhaps the more critical long-term threat is a rapidly shifting competitive landscape. On December 16, dm-drogerie markt launched its “dm-med” platform, launching a direct assault on the over-the-counter medication market. The company is strategically shipping orders from the Czech Republic, a move that puts pressure on Redcare Pharmacy’s cost structure.
In a defensive response, Redcare has already Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
